A carregar...

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

OBJECTIVE: Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Nishio, Makoto, Hida, Toyoaki, Atagi, Shinji, Sakai, Hiroshi, Nakagawa, Kazuhiko, Takahashi, Toshiaki, Nogami, Naoyuki, Saka, Hideo, Takenoyama, Mitsuhiro, Maemondo, Makoto, Ohe, Yuichiro, Nokihara, Hiroshi, Hirashima, Tomonori, Tanaka, Hiroshi, Fujita, Shiro, Takeda, Koji, Goto, Koichi, Satouchi, Miyako, Isobe, Hiroshi, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5566979/
https://ncbi.nlm.nih.gov/pubmed/28861280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!